Compounded Tirzepatide: What It Is, How It Works, and What You Need to Know

What Is Compounded Tirzepatide?

Compounded tirzepatide is tirzepatide that has been prepared by a licensed compounding pharmacy rather than manufactured by Eli Lilly. The active molecule is chemically identical to the tirzepatide in Mounjaro and Zepbound, but the finished product has not gone through FDA's drug approval process as a finished dosage form. Compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act may legally prepare copies of FDA-approved drugs when those drugs appear on the FDA's drug shortage list.

Tirzepatide appeared on that shortage list beginning in 2022 alongside the explosive demand following Mounjaro's approval for type 2 diabetes. During the shortage period, 503A and 503B pharmacies filled a real gap for patients who could not obtain the branded product. The FDA declared the tirzepatide shortage resolved in late 2024, which triggered legal pressure on compounders to wind down production. Patients who had been relying on compounded versions faced a transition decision.

The practical difference between compounded and brand-name tirzepatide comes down to three factors: manufacturing oversight, excipients, and cost. FDA-approved Zepbound and Mounjaro are made in validated facilities under current Good Manufacturing Practice (cGMP) regulations, with every batch tested for potency, sterility, and stability before release. Compounded preparations at 503B outsourcing facilities face similar but not identical federal oversight. 503A retail pharmacies, which prepare individual patient prescriptions, face lighter federal scrutiny and primarily state-level pharmacy board oversight. The FDA has raised concerns about dosing accuracy and sterility in some compounded GLP-1 products, making pharmacy selection a genuine clinical consideration rather than a footnote.

How Tirzepatide Works (and Why It Differs from Semaglutide)

Tirzepatide targets two receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Semaglutide, the active ingredient in Ozempic and Wegovy, targets only the GLP-1 receptor. That dual mechanism is why tirzepatide tends to produce larger weight reductions in head-to-head comparisons.

GLP-1 receptor activation slows gastric emptying, suppresses appetite, and stimulates glucose-dependent insulin secretion. GIP receptor activation adds a complementary signal that may amplify insulin secretion, reduce glucagon, and act on adipose tissue to shift energy balance. The combined effect appears to be more than additive.

SURMOUNT-1 (N=2,539, tirzepatide vs. placebo in adults with obesity or overweight plus at least one comorbidity, no diabetes) showed mean weight loss of 15.0% with 5 mg, 19.5% with 10 mg, and 22.5% with 15 mg at 72 weeks, compared to 2.4% with placebo [1]. By contrast, STEP-1 (N=1,961, semaglutide 2.4 mg vs. placebo) showed mean weight loss of 14.9% at 68 weeks [2]. The difference in peak efficacy between the two agents is approximately 7 to 8 percentage points at maximally tolerated doses, though direct head-to-head randomized data comparing the two in the same trial are still limited.

SURMOUNT-4 (N=670, JAMA 2024) added an important maintenance finding: participants who discontinued tirzepatide after 36 weeks of treatment regained about 14% of body weight over the subsequent 52 weeks, while those who continued the drug maintained their loss and lost a further 5.5% [3]. Weight regain after stopping is a consistent finding across this drug class and reinforces that these medications treat a chronic condition rather than providing a short course fix.

Compounded Tirzepatide vs. Mounjaro vs. Zepbound: What's Actually Different

Mounjaro (tirzepatide, Eli Lilly) carries FDA approval for glycemic control in adults with type 2 diabetes [4]. Zepbound (tirzepatide, Eli Lilly) carries FDA approval for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related condition [5]. The active ingredient and the dose titration schedule are the same across both products. The differences are the labeled indication, the pen device, and the price.

Compounded tirzepatide contains the same active molecule but arrives in a multi-dose vial requiring the patient to draw and inject a measured dose using a syringe. Brand-name Mounjaro and Zepbound use single-dose autoinjector pens that are pre-filled and pre-set, reducing the risk of dosing error. Patients using compounded vials must be trained on reconstitution (if lyophilized) and accurate measurement. A misjudged dose by even 0.1 mL can represent a clinically meaningful deviation at higher concentration formulations.

Cost is the primary reason patients seek compounded versions. Zepbound's list price runs approximately $1,059 per month for the 15 mg dose as of early 2025. Compounded tirzepatide from a 503B outsourcing facility has been priced between $200 and $550 per month depending on dose and pharmacy. For patients without insurance coverage for anti-obesity medications, that gap is the difference between access and no access.

HealthRX Prescriber Decision Framework: Brand-Name vs. Compounded Tirzepatide

| Factor | Favor Brand-Name | Favor Compounded (if legally available) | |---|---|---| | Insurance coverage | Covered with low copay | No coverage or high copay | | Dosing confidence | New to self-injection | Experienced with syringes | | Regulatory timeline | Shortage resolved, compounding winding down | Active shortage period (check FDA list) | | Comorbidity complexity | Multiple metabolic conditions, closer monitoring needed | Straightforward obesity, stable health | | Pharmacy access | Local specialty pharmacy carries branded product | Verified 503B pharmacy available |

Prescribers should check the FDA Drug Shortage Database before writing for compounded tirzepatide. Writing a compounded prescription when the FDA shortage has been resolved may expose both the pharmacy and the prescriber to regulatory risk.

Compounded Tirzepatide vs. Compounded Semaglutide

Semaglutide, the active ingredient in Ozempic (2 mg, T2D) and Wegovy (2.4 mg, obesity), was also subject to an FDA shortage declaration that enabled compounding, and the FDA declared the semaglutide shortage resolved in early 2024. The regulatory path for compounded semaglutide preceded that for tirzepatide by roughly six to nine months.

From a pharmacology standpoint, semaglutide's single-receptor mechanism produces meaningful but generally lower peak weight loss. STEP-1 reported 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg vs. 2.4% with placebo [2]. STEP-5 (N=304, 104-week extension) showed durable weight loss of 15.2% at two years, demonstrating that the effect is sustained with continued use [6].

Semaglutide's cardiovascular outcomes data are more mature. The SELECT trial (N=17,604, semaglutide 2.4 mg vs. placebo in adults with established cardiovascular disease and obesity but without diabetes) reported a 20% reduction in major adverse cardiovascular events (MACE) over a mean follow-up of 39.8 months, with a hazard ratio of 0.80 (95% CI 0.72 to 0.90, P<0.001) [7]. Comparable powered cardiovascular outcomes data for tirzepatide are not yet published, though the SURPASS-CVOT trial is ongoing.

The AACE/ACE Obesity Clinical Practice Guidelines state: "Pharmacotherapy for obesity should be used as an adjunct to comprehensive lifestyle intervention in patients who have not achieved clinically meaningful weight loss through lifestyle modification alone, and in those with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one obesity-related complication." [8] That language applies equally to branded and, during shortage periods, compounded GLP-1 and dual GIP/GLP-1 agonists.

Dosing and Titration for Compounded Tirzepatide

The titration schedule for compounded tirzepatide mirrors the schedule on the Zepbound FDA label [5]. Patients start at 2.5 mg subcutaneously once weekly for four weeks, then step up to 5 mg once weekly. Further increases in 2.5 mg increments occur at four-week intervals based on tolerability, targeting maintenance doses of 5 mg, 10 mg, or 15 mg per week.

Injection sites rotate among the abdomen, thigh, and upper arm. The drug should be given on the same day each week. If a dose is missed by more than four days, patients should skip that dose and resume on the next scheduled injection day. Dose reductions are appropriate for patients experiencing persistent nausea, vomiting, or more than mild gastrointestinal symptoms.

In SURMOUNT-3 (N=579, tirzepatide after a 12-week intensive lifestyle intervention), patients who ran a mean baseline BMI of 38.7 kg/m2 and had already lost a mean 6.9% of body weight through lifestyle alone went on to lose an additional 18.4% with tirzepatide vs. 2.5% with placebo over 72 weeks [9]. That suggests tirzepatide amplifies rather than replaces behavioral changes.

Side Effects and Contraindications

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. In SURMOUNT-1, nausea affected 28 to 33% of tirzepatide-treated participants (dose-dependent) vs. 9% of placebo [1]. Most GI symptoms are transient, peaking during dose escalation and declining over weeks.

Serious but less common risks include:

• Acute pancreatitis (rate in SURMOUNT-1: 0.3% tirzepatide vs. 0.1% placebo)
• Cholelithiasis (gallstones), reported in 1.8% of tirzepatide patients vs. 0.8% placebo in SURMOUNT-1
• Hypoglycemia, primarily when combined with sulfonylureas or insulin
• Injection-site reactions
• Tachycardia (mean increase of 2 to 4 bpm, dose-related)

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This contraindication applies equally to compounded and brand-name formulations because the molecule is the same.

Pregnancy and breastfeeding: tirzepatide is not recommended during pregnancy. Patients planning pregnancy should discontinue at least two months before attempting conception, per the Zepbound FDA label [5].

What to Look for in a Compounding Pharmacy

Not all compounding pharmacies carry equal risk. Patients and prescribers should verify:

1. 503B outsourcing facility registration. The FDA maintains a public list of registered 503B facilities at fda.gov. These facilities operate under federal cGMP standards and conduct batch testing for potency and sterility.

2. Certificate of Analysis (CoA) availability. A reputable pharmacy should provide third-party CoA documentation confirming tirzepatide concentration and absence of contaminants on request.

3. State pharmacy board licensing. Confirm the pharmacy holds an active license in the patient's state of residence.

4. No acetate salt substitution. The FDA has specifically flagged compounded products containing tirzepatide acetate rather than the approved base form as potentially adulterated. Ask the pharmacy directly which salt form they use.

5. Prescriber relationship. Legitimate compounding pharmacies require a valid prescription from a licensed provider. Dispensing without one is a red flag.

How Compounded Tirzepatide Fits Alongside Ozempic, Wegovy, Mounjaro, and Zepbound

Patients searching for weight-loss medications often encounter all four brand names before landing on compounded options. Here is a direct comparison.

Ozempic (semaglutide 0.5, 1 to 2 mg): FDA-approved for type 2 diabetes. Frequently prescribed off-label for obesity. The 1 mg dose produced 6.2 kg weight loss in STEP-2 (N=1,210, T2D population) over 68 weeks [10]. Not FDA-approved for obesity management specifically.

Wegovy (semaglutide 2.4 mg): FDA-approved for chronic weight management. STEP-1 demonstrated 14.9% mean weight loss over 68 weeks [2]. SELECT showed a 20% MACE reduction in high-cardiovascular-risk patients [7]. The cardiovascular label expansion makes Wegovy the only obesity medication with an FDA-approved cardiovascular risk reduction indication as of early 2025.

Mounjaro (tirzepatide 2.5 to 15 mg): FDA-approved for type 2 diabetes. The SURMOUNT-2 trial (N=938, tirzepatide in T2D with obesity) showed mean weight reductions of 13.4% (10 mg) and 15.7% (15 mg) vs. 3.3% placebo over 72 weeks [11].

Zepbound (tirzepatide 2.5 to 15 mg): FDA-approved for chronic weight management. SURMOUNT-1 showed peak 22.5% mean weight loss with 15 mg [1]. The Zepbound FDA label also now includes moderate-to-severe obstructive sleep apnea as an indication in adults with obesity [5].

Compounded tirzepatide: same active molecule as Mounjaro and Zepbound, lower cost, no branded autoinjector device, availability subject to FDA shortage status, variable pharmacy quality. During a declared shortage, a viable access option. Outside a declared shortage, prescribing it carries regulatory and safety considerations that prescribers must weigh explicitly.

Dr. Beverly Tchang, obesity medicine specialist and assistant professor at Weill Cornell Medicine, has stated publicly: "The concern with compounded GLP-1s is not just whether the active drug is present but whether dosing accuracy and sterility meet the standard we expect from an FDA-approved product." That concern applies with equal force to compounded tirzepatide.

Insurance, Prior Authorization, and the Cost Reality

Most commercial insurance plans require prior authorization for Zepbound and Mounjaro when used for obesity. Medicare Part D covers Zepbound for weight management as of 2026 under the Inflation Reduction Act provisions, but coverage varies by plan in 2025. Patients with type 2 diabetes have a clearer path to Mounjaro coverage because T2D is a more routinely covered indication.

For patients without coverage, manufacturer savings programs exist: Eli Lilly's savings card for Zepbound has offered eligible commercially insured patients prices as low as $25 per month, and a self-pay "vial" option launched in 2024 at $399, $549 per month for lower-dose presentations. That price point narrows the gap between brand-name and compounded options for some patients.

STEP-3 (N=611, semaglutide 2.4 mg plus intensive behavioral therapy vs. semaglutide plus standard care) found that adding intensive behavioral therapy produced 16.0% vs. 13.7% weight loss at 68 weeks [12]. The behavioral component added approximately 2.3 percentage points of additional weight loss, a finding that applies regardless of whether a patient is on branded or compounded tirzepatide.

Monitoring While on Tirzepatide

Baseline and ongoing monitoring recommendations for patients on tirzepatide, whether branded or compounded, align with the Endocrine Society's clinical practice guidance:

• Baseline: fasting glucose, HbA1c, comprehensive metabolic panel, lipid panel, thyroid function, body weight, and blood pressure.
• At 12 weeks: weight, tolerability assessment, dose adjustment decision. If a patient has not lost at least 5% of body weight by week 12 to 16 at the target maintenance dose, the prescriber should reassess adherence, dose adequacy, and whether the medication is appropriate.
• Ongoing: weight and blood pressure at each visit; annual metabolic labs; gallbladder evaluation if symptoms suggest cholelithiasis; heart rate monitoring given the modest tachycardia signal.

Patients on concurrent sulfonylureas or insulin need glucose monitoring intensified during dose escalation to watch for hypoglycemia. Dose reductions of the insulin or sulfonylurea are often appropriate before starting tirzepatide.